{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:25:46Z","timestamp":1789194346398,"version":"build-2803163510"},"reference-count":8,"publisher":"Society of Nuclear Medicine","issue":"Supplement 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,6,6]]},"published-print":{"date-parts":[[2026,9]]},"DOI":"10.2967\/jnumed.125.269608","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:40:16Z","timestamp":1789152016000},"page":"3S-4S","source":"Crossref","is-referenced-by-count":1,"title":["Are Urooncologists Onboard?"],"prefix":"10.2967","volume":"67","author":[{"given":"Boris","family":"Hadaschik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026091111400899000_67.Supplement_2.3S.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"2026091111400899000_67.Supplement_2.3S.2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.euo.2024.04.005","article-title":"A comparison of globally applied prognostic risk groups and the prevalence of metastatic disease on prostate-specific membrane antigen positron emission tomography in patients with newly diagnosed prostate cancer","volume":"8","author":"Luining","year":"2025","journal-title":"Eur Urol Oncol."},{"key":"2026091111400899000_67.Supplement_2.3S.3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.euo.2022.01.001","article-title":"Prostate-specific membrane antigen positron emission tomography\/computed tomography is associated with improved oncological outcome in men treated with salvage radiation therapy for biochemically recurrent prostate cancer","volume":"5","author":"Meijer","year":"2022","journal-title":"Eur Urol Oncol."},{"key":"2026091111400899000_67.Supplement_2.3S.4","unstructured":"FDA expands Pluvicto\u2019s metastatic castration-resistant prostate cancer indication. U.S. FDA website. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication. Updated March 28, 2025. Accessed June 25, 2025."},{"key":"2026091111400899000_67.Supplement_2.3S.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026091111400899000_67.Supplement_2.3S.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"2026091111400899000_67.Supplement_2.3S.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00009-9"},{"key":"2026091111400899000_67.Supplement_2.3S.8","doi-asserted-by":"crossref","first-page":"LBA18","DOI":"10.1200\/JCO.2025.43.5_suppl.LBA18","article-title":"Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial [abstract]","volume":"43","author":"Agarwal","year":"2025","journal-title":"J Clin Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.269608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:40:19Z","timestamp":1789152019000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.269608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":8,"journal-issue":{"issue":"Supplement 2","published-online":{"date-parts":[[2026,9,11]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.2967\/jnumed.125.269608"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.269608","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}